Cost-effectiveness of viral hepatitis B & C treatment

Research output: Contribution to journalReview articleAcademicpeer-review

12 Citations (Scopus)


With the availability of effective antiviral therapies for chronic viral hepatitis B and C, cost-effectiveness studies have been performed to assess the outcomes and costs of these therapies to support health policy. It is now accepted that treatment of active CHB is cost-effective versus no treatment, although there are a variety of options. And with the new developments around CHC treatment and diagnostic tools it is of interest to both the clinician and policy makers to know both the costs and effects of these choices. The purpose of this article is to provide the reader with an insight into the recent treatment developments and cost-effectiveness issues related to chronic hepatitis B and C treatment, and an overview of recent cost-effectiveness studies evolving around HBV and HCV therapy.

Original languageEnglish
Pages (from-to)973-985
Number of pages13
JournalBest Practice & Research in Clinical Gastroenterology
Issue number6
Publication statusPublished - Dec 2013
Externally publishedYes

Bibliographical note

Copyright © 2013 Elsevier Ltd. All rights reserved.


Dive into the research topics of 'Cost-effectiveness of viral hepatitis B & C treatment'. Together they form a unique fingerprint.

Cite this